Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

333 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search.
Roodenrijs NMT, Welsing PMJ, van Roon J, Schoneveld JLM, van der Goes MC, Nagy G, Townsend MJ, van Laar JM. Roodenrijs NMT, et al. Among authors: van der goes mc, van roon j, van laar jm. Rheumatology (Oxford). 2022 Aug 30;61(9):3552-3566. doi: 10.1093/rheumatology/keac114. Rheumatology (Oxford). 2022. PMID: 35238332 Free PMC article. Review.
Contribution of the subjective components of the disease activity score to the response to biologic treatment in rheumatoid arthritis.
Jurgens MS, Overman CL, Jacobs JW, Geenen R, Cuppen BV, Marijnissen AC, Bijlsma JW, Welsing PM, Lafeber FP, van Laar JM; Utrecht Arthritis Cohort Study Group. Jurgens MS, et al. Among authors: van laar jm. Arthritis Care Res (Hoboken). 2015 Jul;67(7):923-8. doi: 10.1002/acr.22532. Arthritis Care Res (Hoboken). 2015. PMID: 25504811 Free article. Clinical Trial.
Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy.
Teitsma XM, Jacobs JWG, Welsing PMJ, Pethö-Schramm A, Borm MEA, Hendriks L, Denissen NHAM, van Laar JM, Lafeber FPJG, Bijlsma JWJ. Teitsma XM, et al. Among authors: van laar jm. Rheumatology (Oxford). 2017 Dec 1;56(12):2179-2189. doi: 10.1093/rheumatology/kex319. Rheumatology (Oxford). 2017. PMID: 29029185 Clinical Trial.
Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors.
Teitsma XM, Jacobs JWG, Welsing PMJ, de Jong PHP, Hazes JMW, Weel AEAM, Pethö-Schramm A, Borm MEA, van Laar JM, Lafeber FPJG, Bijlsma JWJ. Teitsma XM, et al. Among authors: van laar jm. Ann Rheum Dis. 2018 Sep;77(9):1261-1267. doi: 10.1136/annrheumdis-2018-213035. Epub 2018 May 14. Ann Rheum Dis. 2018. PMID: 29760159 Clinical Trial.
Effect on Costs and Quality-adjusted Life-years of Treat-to-target Treatment Strategies Initiating Methotrexate, or Tocilizumab, or Their Combination in Early Rheumatoid Arthritis.
Verhoeven MMA, Tekstra J, van Laar JM, Pethö-Schramm A, Borm MEA, Bijlsma JWJ, Jacobs JWG, Lafeber FPJG, Welsing PMJ. Verhoeven MMA, et al. Among authors: van laar jm. J Rheumatol. 2021 Apr;48(4):495-503. doi: 10.3899/jrheum.200067. Epub 2020 Aug 1. J Rheumatol. 2021. PMID: 32739893
333 results